• 1. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 2. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines

Introduction to 4(3H)-Quinazolinone,6,8-diiodo- (CAS No: 100540-61-2) and Its Emerging Applications in Chemical Biology and Medicinal Chemistry

4(3H)-Quinazolinone,6,8-diiodo-, identified by its Chemical Abstracts Service (CAS) number 100540-61-2, is a structurally intriguing heterocyclic compound that has garnered significant attention in the fields of chemical biology and medicinal chemistry. This review provides a comprehensive overview of the compound's chemical properties, synthetic methodologies, and its promising applications in drug discovery and therapeutic development.

The quinazolinone scaffold is a well-documented pharmacophore in medicinal chemistry, known for its broad spectrum of biological activities. The introduction of iodine substituents at the 6- and 8-positions of the quinazolinone core (4(3H)-Quinazolinone,6,8-diiodo-) introduces unique electronic and steric properties that enhance its reactivity and potential utility in various biochemical processes. The compound's diiodo substitution pattern makes it a valuable intermediate for further functionalization, enabling the synthesis of more complex derivatives with tailored biological properties.

In recent years, 4(3H)-Quinazolinone,6,8-diiodo- has been extensively studied for its role in modulating key biological pathways. One of the most compelling areas of research involves its potential as an inhibitor of tyrosine kinases, which are overexpressed in numerous cancers. Studies have demonstrated that the iodinated quinazolinone derivatives exhibit potent inhibitory activity against src-family kinases, including c-Src and Fyn. The iodine atoms serve as critical recognition elements for binding to the ATP-binding pocket of these kinases, thereby disrupting their catalytic activity.

Furthermore, the diiodo-substituted quinazolinone scaffold has been explored as a precursor for the development of radiolabeled probes used in positron emission tomography (PET) imaging. The high affinity of iodine for radioactive isotopes such as iodine-123 or iodine-125 makes this compound an ideal candidate for creating targeted imaging agents. Such agents have shown great promise in early detection and staging of solid tumors, providing clinicians with non-invasive tools to monitor disease progression and treatment response.

The synthetic route to 4(3H)-Quinazolinone,6,8-diiodo- involves a multi-step process that typically begins with the condensation of anthranilic acid derivatives with urea or thiourea to form the quinazolinone core. Subsequent halogenation using molecular iodine or N-iodosuccinimide (NIS) under controlled conditions yields the diiodo-substituted product. Recent advancements in synthetic methodology have focused on optimizing reaction conditions to improve yield and purity while minimizing side reactions. For instance, microwave-assisted synthesis has been employed to accelerate the halogenation step, reducing reaction times from hours to minutes without compromising product integrity.

The biological activity of 4(3H)-Quinazolinone,6,8-diiodo- has also been investigated in the context of antimicrobial and antiviral applications. Preliminary studies suggest that certain derivatives exhibit inhibitory effects against Gram-positive bacteria by interfering with bacterial DNA gyrase activity. The iodine substituents enhance binding affinity to bacterial topoisomerases, disrupting DNA replication and transcription processes. Similarly, research into antiviral applications has shown that modified quinazolinones can inhibit viral polymerase enzymes by competing with natural substrates or inducing conformational changes in viral proteins.

From a computational chemistry perspective, molecular modeling studies have been instrumental in understanding the binding interactions between 4(3H)-Quinazolinone,6,8-diiodo- and its target proteins. Advanced techniques such as docking simulations and molecular dynamics (MD) simulations have revealed detailed insights into how the iodine atoms interact with amino acid residues in kinase active sites. These studies not only aid in rational drug design but also provide a foundation for developing structure-based inhibitors with improved selectivity and reduced toxicity.

The pharmacokinetic properties of 4(3H)-Quinazolinone,6,8-diiodo- derivatives are another critical area of investigation. Understanding how these compounds are absorbed, distributed, metabolized, and excreted (ADME) is essential for optimizing their therapeutic potential. In vitro studies using liver microsomes have shown that certain derivatives undergo rapid metabolism via cytochrome P450 enzymes, suggesting that drug-drug interactions may be a concern in clinical settings. Efforts are underway to develop more stable analogs with improved metabolic profiles while maintaining biological activity.

Future directions in the study of 4(3H)-Quinazolinone,6,8-diiodo- include exploring its potential as a scaffold for next-generation anticancer agents. By integrating principles from fragment-based drug design and structure-based optimization strategies, researchers aim to develop novel compounds that exhibit higher potency and better selectivity against cancer cell lines. Additionally, investigating the compound's role in modulating immune responses has opened new avenues for treating autoimmune diseases and enhancing vaccine efficacy.

In conclusion,4(3H)-Quinazolinone, particularly its diiodo-substituted derivative identified by CAS No: 100540-61-2, represents a versatile intermediate with significant potential across multiple domains of chemical biology and medicinal chemistry. Its applications in kinase inhibition, PET imaging, antimicrobial therapy, computational modeling, pharmacokinetic studies, and oncology research underscore its importance as a building block for innovative therapeutics. As research continues to uncover new biological functions and synthetic strategies, this compound is poised to play an increasingly pivotal role in addressing unmet medical needs.

• 16064-08-7(6-iodo-3,4-dihydroquinazolin-4-one)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)